Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATShares Outstanding
Ratios

Alaunos Therapeutics (TCRT) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Alaunos Therapeutics (TCRT) over the last 13 years, with Q4 2024 value amounting to $15000.0.

  • Alaunos Therapeutics' Accumulated Depreciation & Amortization rose 1538.46% to $15000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $15000.0, marking a year-over-year increase of 1538.46%. This contributed to the annual value of $15000.0 for FY2024, which is 1538.46% up from last year.
  • Alaunos Therapeutics' Accumulated Depreciation & Amortization amounted to $15000.0 in Q4 2024, which was up 1538.46% from $13000.0 recorded in Q4 2023.
  • Alaunos Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $9.8 million for Q4 2022, and its period low was $13000.0 during Q4 2023.
  • In the last 5 years, Alaunos Therapeutics' Accumulated Depreciation & Amortization had a median value of $5.0 million in 2020 and averaged $4.4 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 4939.54% in 2021, then plummeted by 9986.74% in 2023.
  • Over the past 5 years, Alaunos Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $5.0 million in 2020, then soared by 49.4% to $7.4 million in 2021, then surged by 32.29% to $9.8 million in 2022, then tumbled by 99.87% to $13000.0 in 2023, then rose by 15.38% to $15000.0 in 2024.
  • Its Accumulated Depreciation & Amortization stands at $15000.0 for Q4 2024, versus $13000.0 for Q4 2023 and $9.8 million for Q4 2022.